Immunotherapy Response & Immune-Related Findings on FDG-PET

Quick Answer

Immune-checkpoint inhibitors changed how FDG-PET is read in oncology. Two things must be recognized: atypical response patterns — chiefly pseudoprogression (lesions transiently enlarge or become more avid from immune-cell infiltration before responding) and the much rarer hyperprogression (genuine accelerated growth) — and immune-related adverse events (irAEs), which appear on FDG-PET as new inflammatory uptake in organs: thyroid, colon, lung, pituitary/adrenal, joints, and more. Standard size-based progression (RECIST) misclassifies pseudoprogression, so immune-adapted criteria (iRECIST, and PET-specific schemes) require confirmation on a follow-up scan before calling true progression.

Why immunotherapy breaks ordinary response reading

Checkpoint inhibitors work by recruiting immune cells into tumor, and activated immune cells are FDG-avid. So early after starting therapy a responding lesion can grow and light up more from lymphocytic infiltration — pseudoprogression — an appearance identical to true progression on a single scan. The discriminator is the same as for the flare phenomenon: trajectory and confirmation, not one time point. Apparent progression must be confirmed ~4–8 weeks later (iRECIST "unconfirmed" vs "confirmed" progression) before therapy is abandoned.

Response patterns to know

The immune-response vocabulary the boards test:

• Pseudoprogression — early apparent growth/increased uptake that later regresses; driven by immune infiltration; confirm, don't abandon.
• Hyperprogression — real, paradoxically accelerated tumor growth after starting immunotherapy (a minority, associated with worse outcome); the scan worsens and keeps worsening with clinical decline.
• Dissociated (mixed) response — some lesions respond while others progress; whole-body PET is well suited to detect it.
• Durable response / complete metabolic response — often deep and long-lasting once achieved.

Several PET-specific immune response frameworks exist (e.g. PERCIMT, imPERCIST, iPERCIST) that, like iRECIST, build in confirmation of progression and account for new lesions differently from PERCIST. The unifying rule across all of them: a single scan cannot call immunotherapy failure — timing and a confirmatory study are required.

Immune-related adverse events on FDG-PET

irAEs are inflammatory and therefore FDG-avid, often detected on PET before symptoms. Recognize the organ patterns:

• Thyroiditis — diffuse thyroid uptake (may precede hypothyroidism).
• Colitis — diffuse or segmental bowel-wall uptake (a clinically important, sometimes severe irAE).
• Pneumonitis — new parenchymal/ground-glass uptake.
• Hypophysitis — pituitary enlargement/uptake (with endocrine failure).
• Sarcoid-like reaction — new symmetric hilar/mediastinal nodal uptake mimicking progression — a classic pitfall.
• Arthritis, hepatitis, adrenalitis, myocarditis — organ-specific uptake.

The sarcoid-like reaction and new nodal uptake from immune activation are the highest-yield pitfalls: new FDG-avid mediastinal/hilar nodes on immunotherapy are not automatically metastatic — an immune-mediated (sarcoid-like) reaction is a well-described mimic, and misreading it as progression can wrongly stop an effective drug.

How to report it

Integrate timing since therapy start, trajectory across scans, clinical status, and the organ pattern. Flag possible irAEs (especially colitis, pneumonitis, hypophysitis) because they are actionable — they may require steroids or drug interruption. For apparent progression early on, recommend confirmatory imaging rather than a definitive "progression" call.

Common Pitfalls / Cautions

• Calling pseudoprogression "progression" on a single early scan — the cardinal error; confirm first.
• Sarcoid-like nodal reaction misread as nodal metastasis.
• irAE uptake (thyroid, bowel, lung) mistaken for new malignancy — or missed when it is actually a treatable toxicity.

Board Pearls

• Activated immune cells are FDG-avid — the single mechanism behind both pseudoprogression and immune-related adverse-event uptake.
• Under immune-adapted criteria, new lesions do not automatically equal progression and apparent progression must be confirmed on a follow-up scan before therapy is abandoned.
• irAEs are often visible on PET before symptoms and are actionable (may need steroids or drug interruption) — actively look for them.
• A sarcoid-like reaction produces new symmetric hilar/mediastinal nodes; when biopsied it shows non-caseating granulomas, not tumor.
• Hyperprogression (a minority, worse outcome) is distinguished from pseudoprogression by continued worsening with clinical decline, not later regression.

Differential Diagnosis

• New mediastinal/hilar nodal uptake: immune-mediated sarcoid-like reaction versus nodal metastasis.
• New diffuse thyroid uptake: immune thyroiditis versus (rarely) malignancy.
• Bowel-wall uptake: immune colitis versus physiologic bowel activity versus metastasis.
• Pituitary enlargement/uptake: hypophysitis versus pituitary metastasis.
• Diffuse marrow/splenic uptake: cytokine/immune activation (or G-CSF effect) versus marrow disease.
• Growing/more-avid lesion early on: pseudoprogression versus true progression versus hyperprogression — resolved by trajectory and confirmation.

Reporting Checklist

• State the interval since immunotherapy start and reference prior scans for trajectory.
• Score using an immune-adapted framework (iRECIST / PET-specific) and label apparent progression as unconfirmed pending follow-up.
• Enumerate suspected irAEs by organ and flag them as actionable.
• Distinguish a sarcoid-like nodal reaction from metastatic nodes; recommend biopsy or follow-up when uncertain.
• Note any dissociated (mixed) response across lesions.
• Give an explicit confirmatory-imaging recommendation and timing when progression is equivocal.

Self-Check

Key References

• Immune-adapted response criteria — iRECIST; PET-specific frameworks (PERCIMT, imPERCIST/iPERCIST) addressing confirmation of progression and new lesions.
• Reviews of immune-related adverse events on FDG-PET/CT and the sarcoid-like reaction as a progression mimic.